Literature DB >> 11445059

Bradyarrhythmias.

Thomas J. Dresing1, Bruce L Wilkoff.   

Abstract

In our opinion, the term bradyarrhythmia should be reserved for bradycardias (heart rates less than 60) that are associated with symptoms such as syncope or near-syncope, congestive heart failure, exercise intolerance, fatigue, or a confusional state that improves with resolution of the bradycardia. The mere presence of a bradycardia that is not associated with these symptoms almost never justifies aggressive intervention, with few notable exceptions. It is important to determine if the bradyarrhythmia will not resolve spontaneously or with the alleviation of a condition that is the likely cause of the bradyarrhythmia. If a hemodynamically stable patient can be observed safely while being treated for a metabolic or ischemic condition or an adverse drug reaction, then it is not justified to implant a permanent pacemaker, though a temporary pacemaker may be necessary in the interim. Certain forms of reflex-mediated syncope have an element of inappropriate bradycardia that may be amenable to pacing. Pacemaker implantation should be considered for patients with recurrent vasovagal or situational syncope that is refractory to other therapies. The treatment of specific bradyarrhythmias should be in accordance with the guidelines laid forth by the joint councils of the American Heart Association and the American College of Cardiology.

Entities:  

Year:  2001        PMID: 11445059     DOI: 10.1007/s11936-001-0091-9

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  7 in total

1.  The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope.

Authors:  S J Connolly; R Sheldon; R S Roberts; M Gent
Journal:  J Am Coll Cardiol       Date:  1999-01       Impact factor: 24.094

2.  Oral disopyramide in the treatment of recurrent neurocardiogenic syncope.

Authors:  S K Bhaumick; S Morgan; B K Mondal
Journal:  Int J Clin Pract       Date:  1997 Jul-Aug       Impact factor: 2.503

3.  "Rate-drop response" cardiac pacing for vasovagal syncope. Rate-Drop Response Investigators Group.

Authors:  D G Benditt; R Sutton; M Gammage; T Markowitz; J Gorski; G Nygaard; J Fetter
Journal:  J Interv Card Electrophysiol       Date:  1999-03       Impact factor: 1.900

4.  Dual-chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope : pacemaker versus no therapy: a multicenter randomized study. The Vasovagal Syncope International Study (VASIS) Investigators.

Authors:  R Sutton; M Brignole; C Menozzi; A Raviele; P Alboni; P Giani; A Moya
Journal:  Circulation       Date:  2000-07-18       Impact factor: 29.690

Review 5.  Permanent pacemakers in older persons.

Authors:  G Gregoratos
Journal:  J Am Geriatr Soc       Date:  1999-09       Impact factor: 5.562

Review 6.  Pharmacotherapy of neurally mediated syncope.

Authors:  D G Benditt; G J Fahy; K G Lurie; S Sakaguchi; W Fabian; N Samniah
Journal:  Circulation       Date:  1999-09-14       Impact factor: 29.690

7.  Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy.

Authors:  J Sra; C Maglio; M Biehl; A Dhala; Z Blanck; S Deshpande; M R Jazayeri; M Akhtar
Journal:  J Cardiovasc Electrophysiol       Date:  1997-01
  7 in total
  1 in total

1.  Inhaled ambient-level traffic-derived particulates decrease cardiac vagal influence and baroreflexes and increase arrhythmia in a rat model of metabolic syndrome.

Authors:  Alex P Carll; Samir M Crespo; Mauricio S Filho; Douglas H Zati; Brent A Coull; Edgar A Diaz; Rodrigo D Raimundo; Thomas N G Jaeger; Ana Laura Ricci-Vitor; Vasileios Papapostolou; Joy E Lawrence; David M Garner; Brigham S Perry; Jack R Harkema; John J Godleski
Journal:  Part Fibre Toxicol       Date:  2017-05-25       Impact factor: 9.400

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.